Please wait while the formulary information is being retrieved.
SOMAVERT (PEGVISOMANT)
- Acromegaly
10 mg subcutaneous solution
- Inject 10 mg by subcutaneous route once daily
15 mg subcutaneous solution
- Inject 15 mg by subcutaneous route once daily
20 mg subcutaneous solution
- Inject 20 mg by subcutaneous route once daily
25 mg subcutaneous solution
- Inject 25 mg by subcutaneous route once daily in the abdomen, thigh, upper outer areas of buttocks, or outer area of upper arm (rotate site)
30 mg subcutaneous solution
- Inject 30 mg by subcutaneous route once daily in the abdomen, thigh, upper outer areas of buttocks, or outer area of upper arm (rotate site)
Acromegaly
- Inject 20 mg by subcutaneous route once daily
- Inject 10 mg by subcutaneous route once daily
- Inject 15 mg by subcutaneous route once daily
- Inject 30 mg by subcutaneous route once daily
- Inject 25 mg by subcutaneous route once daily in the abdomen, thighs,upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- Inject 30 mg by subcutaneous route once daily in the abdomen, thighs,upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- Inject 25 mg by subcutaneous route once daily in the abdomen, thigh, upper outer areas of buttocks, or outer area of upper arm (rotate site)
- Inject 30 mg by subcutaneous route once daily in the abdomen, thigh, upper outer areas of buttocks, or outer area of upper arm (rotate site)
- None
Contraindicated
- None
Severe
Moderate
- octreotide acetate
- Sandostatin
- Sandostatin Lar Depot
- None
Contraindicated
- None
Severe
Moderate
- Diabetes mellitus
SOMAVERT (PEGVISOMANT)
- Acromegaly
- Abnormal hepatic function tests
- Chest pain
- Infection
- Upper respiratory infection
- Accidental injury
- Back pain
- Diarrhea
- Dizziness
- Flu-like symptoms
- Hypertension
- Injection site sequelae
- Nausea
- Pain
- Paresthesia
- Peripheral edema
- Sinusitis
More Frequent
Severe
Less Severe
- Increased alanine transaminase
- Increased aspartate transaminase
- Fat hypertrophy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Hyperbilirubinemia
- Laryngismus
Less Severe
- Erythema
- Pruritus of skin
- Skin rash
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pegvisomant
Safety and efficacy not established for treatment of acromegaly.
- 1 Day – 18 Years
- Safety and efficacy not established for treatment of acromegaly.
Pegvisomant
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Pegvisomant
Insuff human data; not orally absorbed
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff human data; not orally absorbed |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Acromegaly | |
E22.0 | Acromegaly and pituitary gigantism |
0-9 | A-Z |
---|---|
E22.0 | Acromegaly and pituitary gigantism |
Formulary Reference Tool